# Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

> **NCT05014815** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 272 (actual)

## Conditions studied

- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
- Nonsmall Cell Lung Cancer, Stage IIIB
- Nonsmall Cell Lung Cancer, Stage IV

## Interventions

- **DRUG:** Ociperlimab
- **DRUG:** Tislelizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05014815
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-09-04
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014815, "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05014815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*